Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Endothelial deletion of the neddylation E2 enzyme UBE2M inhibits tumor growth by promoting nonproductive angiogenesis
Xinyi Jiang, Jie Zhang, Li Zhou, Zonglin Li, Ningcong Sun, Xian Xu, Jisong Zhang, Yizhou Huang, Xue Zhang, Enguo Chen, Hongqiang Cheng, Yuehai Ke
Xinyi Jiang, Jie Zhang, Li Zhou, Zonglin Li, Ningcong Sun, Xian Xu, Jisong Zhang, Yizhou Huang, Xue Zhang, Enguo Chen, Hongqiang Cheng, Yuehai Ke
View: Text | PDF
Research Article Cell biology Vascular biology

Endothelial deletion of the neddylation E2 enzyme UBE2M inhibits tumor growth by promoting nonproductive angiogenesis

  • Text
  • PDF
Abstract

Neddylation is highly activated in many human cancers and may serve as a therapeutic target for clinical treatment. However, the role of neddylation in tumor angiogenesis remains unclear. Here, we demonstrate that the neddylation E2 enzyme UBE2M was upregulated in tip cells and was essential for tumor vascular sprouting. We showed that UBE2M-mediated neddylation of STAT1 enhanced its phosphorylation and promoted the transcription of DLL4. This elevated DLL4 expression in tip cells activated Notch signaling in adjacent stalk cells, thereby maintaining the tip-stalk cell balance and ensuring organized vascular patterning. Consequently, endothelial cell–specific deletion of UBE2M reduced DLL4 expression, leading to excessive but nonproductive sprouting due to uncontrolled tip cell formation and lack of stalk cell support, which ultimately suppressed tumor growth. Importantly, targeting endothelial neddylation potently sensitized various tumors to anti-VEGF therapy. Together, our findings unveil UBE2M as a key regulator of angiogenic signaling and identify it as a promising antiangiogenic target in cancer.

Authors

Xinyi Jiang, Jie Zhang, Li Zhou, Zonglin Li, Ningcong Sun, Xian Xu, Jisong Zhang, Yizhou Huang, Xue Zhang, Enguo Chen, Hongqiang Cheng, Yuehai Ke

×

Figure 7

DLL4 reexpression in tumor endothelial cells restored tumor growth and vasculature in Ube2miECKO mice.

Options: View larger image (or click on image) Download as PowerPoint
DLL4 reexpression in tumor endothelial cells restored tumor growth and v...
(A) Images of B16 melanoma tumors from Ube2mfl/fl and Ube2miECKO mice treated with AAV-DLL4. n = 5 per group (n = 4 for Ube2miECKO) Scale bar: 10 mm. (B and C) Tumor volumes (B) and tumor weights (C) of B16 tumors from Ube2mfl/fl and Ube2miECKO mice treated with AAV-DLL4. Arrows indicated the time points for AAV and tamoxifen injection. Tumor weights were measured 12 days after cancer cell injection. (D and E) Representative images of CD31 staining and hypoxyprobe-1–labeled areas in B16 tumors. Images were analyzed by ImageJ software (n = 5). Scale bar: 100 μm. (F and G) Representative images of B16 tumor necrosis. Necrosis areas were labeled by dotted lines. Images were analyzed by ImageJ software (n = 5). Scale bar: 1 mm. (H–K) Immunofluorescence images of CD31 (H) in B16 tumors. Vessel area (I), average vessel length (J), and total number of end points (K) were measured by ImageJ software (n = 5). Scale bar: 100 μm. (L and M) Immunofluorescence images of CD31 and lectin in B16 tumors. Images were measured by ImageJ software (n = 5). Scale bar: 50 μm. (N and O) Immunofluorescence images of CD31 and CXCR4 in B16 tumors. The proportion of CXCR4+ cells among CD31+ endothelial cells was quantified (n = 5). Scale bar: 50 μm. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Two-way ANOVA with Tukey’s post hoc test (B) or 1-way ANOVA with multiple comparisons (C, E, G, I–K, M, and O).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts